Loading...
Market
Will BioNTech and MediLink successfully complete Phase 1 trial of BNT326/YL202 by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from BioNTech, MediLink Therapeutics, or the FDA
Story
FDA Lifts Hold on BioNTech's BNT326/YL202 Cancer Drug Trial
Aug 19, 2024, 11:40 AM
BioNTech announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on its experimental cancer drug trial. The trial involves BNT326/YL202, an anti-HER3 antibody-drug conjugate (ADC), developed in partnership with MediLink Therapeutics. The FDA's decision allows the companies to restart the phase 1 trial, with the stipulation that only lower doses will be used.
View original story
Similar markets
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Yes • 50%
No • 50%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%